For decades, most African nations have relied heavily on imported pharmaceuticals to meet their healthcare needs. In this analysis, Dr. Arnaud Kaboré—a pharmacist and engineer—outlines a strategic roadmap for policymakers to achieve pharmaceutical sovereignty by 2045.

Why Africa’s pharmaceutical dependence is a growing threat

Despite progress, fewer than five African countries currently operate export-ready pharmaceutical manufacturing facilities. This leaves the continent importing a staggering 94% of its medicines at an annual cost exceeding $18 billion—a figure projected to surpass $30 billion by 2030. Beyond economics, this dependence exposes Africa to severe health vulnerabilities.

Data reveals that over 70% of public health facilities across the continent face critical drug shortages at least once per quarter. Can we justify a situation where the health of 1.4 billion Africans hinges on decisions made outside the continent? The Covid-19 pandemic exposed these risks: essential drugs like amoxicillin, insulin, and anesthetics became scarce, while cancer treatments and innovative therapies remained inaccessible for millions. The human cost is undeniable—untreated illnesses, price surges during shortages, and stalled public health programs.

Africa’s untapped potential in pharmaceutical independence

Yet Africa possesses the building blocks for self-sufficiency:

• A rapidly expanding market: The African pharmaceutical sector could reach $70 billion by 2030 (McKinsey, 2022).

• Rich biodiversity: Over 5,400 medicinal plants have been documented, some already integrated into official therapeutic protocols (African Union).

• Regulatory momentum: The African Medicines Agency (AMA), ratified by 27 countries, is standardizing pharmaceutical norms.

• Political will: Countries like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa have launched ambitious local production initiatives.

Building a sustainable pharmaceutical industry: lessons from Africa

A critical mistake has been attempting to replicate the models of multinational pharmaceutical giants without addressing foundational weaknesses. Industrialization demands more than imported equipment—it requires developing local expertise, technical know-how, and robust supply chains. Without these, local production often becomes costlier than imports, perpetuating dependence on foreign raw materials, technologies, and expertise.

True pharmaceutical sovereignty in Africa will require:

• Strategic prioritization of accessible and high-impact production segments.

• Investment in human capital and technical training.

• Long-term vision aligned with Africa’s unique strengths—its growing market, biodiversity, and regulatory progress.

This roadmap offers policymakers a clear path to reclaim Africa’s pharmaceutical independence by 2045. The goal is simple: produce locally to heal locally. And in time, extend Africa’s pharmaceutical excellence to the world.

Dr. Arnaud Kaboré
Pharmacist & Healthcare Executive Engineer